ResMed Expands COPD Offering as New Data Reveals Benefits of Home Non-Invasive Ventilation
6.9.2016 05:00 | Business Wire
Today ResMed welcomed positive results from the independent Home Oxygen Therapy- Home Mechanical Ventilation (HOT-HMV) study1 regarding the benefits of home non-invasive ventilation (NIV). Portable oxygen therapy, remote monitoring technology and home NIV are key components of ResMed’s COPD management offering.
The HOT-HMV study shows that the addition of home NIV to home oxygen therapy improves admission-free survival in hypercapnic COPD patients (those with high levels of carbon dioxide in the blood) following a life-threatening exacerbation of COPD requiring acute NIV.1 This includes an increase in patients’ median (hospital) admission-free survival from 1.4 months in the group receiving HOT only, to 4.3 months in the group receiving HOT plus home NIV, with an adjusted hazard ratio of 0.49 (0.31-0.77); p=0.002.1
“These results build on and add further weight to existing evidence supporting the broader use of home NIV in patients living with COPD, whilst also underlining the accepted benefits of home NIV in terms of reducing hospital admissions and improving patient outcomes,” said Holger Woehrle, ResMed’s Vice President of Clinical Research and Medical Director of EMEA & APAC. “We hope these results will have a positive impact on current practice and encourage more healthcare professionals to consider the role of home NIV in managing their COPD patients.”
Previous studies also confirm that home NIV can successfully reduce mortality2 and exacerbation-related hospitalisations3 and improve patients’ quality of life.2
ResMed’s at-home COPD offering includes three series of home NIV products, Lumis™, Stellar™ and Astral™, which can be used by COPD patients at different stages of their disease. These solutions ensure pulmonologists can efficiently meet the unique and ever-changing needs of their COPD patients whilst also optimising healthcare professionals’ time and resources.
ResMed home NIV solutions are also connected to AirView™, ResMed’s cloud-based patient management system, which ensures healthcare professionals can remotely identify patients in need of attention, make informed treatment decisions and deliver timely interventions. In addition to helping physicians better manage COPD patients on home NIV, AirView also enables home care providers to optimise business efficiencies and allows them to focus existing resources on high-value activities. Resmed’s cloud-connected ventilators provide peace of mind to patients and their families and help improve their overall experience living with COPD.
With the ambition of improving the lives of more and more patients, ResMed has this week unveiled the newest addition to its growing COPD portfolio: LifeChoiceTM Activox 4LTM portable oxygen concentrator from Inova Labs, which ResMed acquired in early 2016. Highly portable, with class-leading battery autonomy, LifeChoice Activox 4L is less intrusive than traditional oxygen delivery formats. It can help COPD patients who are still mobile to overcome the constraints that options such as tanks and Liquid O2 place on their day-to-day activities. Specially designed for patient comfort, this new solution also allows patients to benefit from smoother oxygen delivery.
“COPD is a debilitating, chronic condition and we have made it our mission as a company to help all COPD patients remain as active and independent as they can be for as long as possible,” said Luke Maguire, ResMed’s President of Cardio-Respiratory Care. “ResMed is proud to take an active role in supporting our partners in the pulmonology community to deliver new at-home technologies that can help to achieve this across the COPD management spectrum – from oxygen therapy, to non-invasive ventilation and remote monitoring.”
Chronic obstructive pulmonary disorder, or COPD, describes a collection of lung diseases including chronic bronchitis, emphysema and chronic obstructive airways disease. It is a progressive, fatal condition that causes irreversible damage to the lungs and airway. COPD leads to difficulty breathing and can have a major impact on an individual’s quality of life. It is one of the leading causes of death worldwide and is the only major disease that is increasing in prevalence globally, across all continents.4,5,6 During the course of their disease, COPD patients can experience acute exacerbations, which manifest themselves as a sudden worsening of symptoms and can lead to respiratory failure, hospitalisation and death. Although the damage caused by COPD cannot be reversed, it is possible to slow the progression of the disease through medical treatment and lifestyle changes.
ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnoea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 2 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.
1 Murphy P. and Hart N. Home Mechanical Ventilation (HMV) Following Life Threatening Exacerbations of COPD: A UK Multicentre Randomised Controlled Trial. Abstract presented at the European Respiratory Society annual congress 2016, London.
2 Köhnlein T, et al. Lancet Respir Med. 2014;2 :698-705
3 Galli J, Krahnke JS, James Mamary A, Shenoy K, Zhao H, Criner GJ. Home non-invasive ventilation use following acute hypercapnic respiratory failure in COPD. Respir Med. 2014 May;108(5):722-8. doi: 10.1016/j.rmed.2014.03.006. Epub 2014 Mar 20.
4 Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. Int J Tuberc Lung Dis 2008; 12: 703–708.
5 Menezes AM, Jardim JR, Peréz-Padilla R, et al. Prevalence of chronic obstructive pulmonary disease and associated factors: the PLATINO Study in Sao Paulo, Brazil. Cad Saude Publica 2005; 21: 1565–1573.
6 Mehrotra A, Oluwole AM, Gordon SB. The burden of COPD in Africa: a literature review and prospective survey of the availability of spirometry for COPD diagnosis in Africa. Trop Med Int Health 2009; 14: 840–848
Marketing Communications, EMEA-APAC
O: +33 4 26 100 243
O: +1 858-836-5971
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
The Valence Group Issues Fairness Opinion to SK Capital in Connection with Archroma18.8.2017 13:30 | Pressemelding
The Valence Group has provided a fairness opinion to SK Capital Partners, LP in connection with its recapitalization of Archroma, including investments made by various affiliates of SK Capital. Terms of the transaction were not disclosed. About SK Capital SK Capital is a private investment firm focused on the specialty materials, chemicals and pharmaceutical sectors. The firm builds strong and growing businesses that generate substantial long-term value for its investors. SK Capital utilizes its industry, operating and investment experience to identify opportunities to transform businesses into higher performing companies with improved strategic positioning, growth, profitability and risk profiles. The firm currently has approximately $1.9 billion of assets under management and its portfolio companies generate revenues of over $5.0 billion annually and employ approximat
Biker Summer 2017 campaign: What’s happening during Biker Summer 2017? Moto-tyres.co.uk is giving away exciting prizes!18.8.2017 09:22 | Pressemelding
Whether it’s a short weekend break or a long-distance tour – once again this year Moto-tyres.co.uk is asking bikers from 10 countries about their dream destinations and longest journeys as part of its “Biker Summer 2017” campaign. To ensure than nothing gets in the way of your next tour, the two-wheeler tyre store from Delticom, Europe’s leading online tyre dealer, is entering anyone who completes the survey before 30 September 2017 into a prize draw to win some great biking accessories. Simply answer three short questions about your plans for bike tours this year (don’t forget to provide your name and email address), and with a bit of luck, you might win one of these great prizes. Up for grabs are a GARMIN motorbike GPS system, a GoPro camera with helmet bracket and five 200-Pound vouchers for new motorbike tyres from the online store – thanks to the product range at Moto-tyres.co.uk, eve
Lenovo Continues to Gain Momentum in First Quarter FY 2017/1818.8.2017 00:04 | Pressemelding
Behind the strength of its 3-wave strategy, Lenovo’s business transformation continued to gain traction during the first quarter, delivering solid profitability in its core PC and smart devices business, and revenue and profit improvements in targeted growth areas, including the data center and mobile businesses. Fueled by new investments in people and products, Lenovo’s Data Center Group (DCG) introduced the most comprehensive product lineup in its history, with the new ThinkSystem and ThinkAgile portfolio, and continued to build out its end-to-end sales organization. Similarly, Lenovo’s Mobile Business Group launched significant new products led by the Moto Z2 Force, available now on all major U.S. carriers, and ramped up its branding efforts worldwide. “In the first quarter this fiscal year, we had stable performance as we executed our 3-wave strategy with commitment. We
Spirent Tests Wi-Fi Network Performance with O2 at the Coca-Cola London Eye17.8.2017 15:57 | Pressemelding
Spirent Communications plc (LSE:SPT), today announced its Landslide E10 network test platform has been used with O2 to validate the Wi-Fi network performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005758/en/ Spirent Landslide E10 helped O2 validate Wi-Fi performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. (Photo: Busines Wire) Merlin Entertainments plc, operator of the London Eye, wanted to measure its Wi-Fi network performance, to ensure its infrastructure could provide an excellent experience for users of the new app, which puts increased demands on the Wi-Fi network. “The London Eye is a global attractio
Watch BizWireTV: A Camera You Can Wear and Krispy Kreme’s Famous Donuts Get Eclipsed with Chocolate17.8.2017 12:08 | Pressemelding
On BizWireTV, catch some Quick Biz Hits and see the latest in Star Power. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005305/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Introducing FrontRow: the camera re-invented. Watch BizWireTV to see more disruptors as well as the top 5 trending stories of the week! A core c
PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence17.8.2017 07:00 | Pressemelding
PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as part of an ongoing drive to expand in the US. Charles Rowland was most recently the President and Chief Executive Officer (CEO) of Aurinia Pharmaceuticals, a clinical stage pharmaceutical company focused on the global lupus nephritis market. Prior to this, he served as the Vice President and Chief Financial Officer (CFO) of ViroPharma, during which time the company grew into a global biopharmaceutical business with $500 million in annual revenues until it was acquired by Shire plc for $4.2 billion. Before joining ViroPharma, Mr. Rowland was executive Vice President, CFO, and interim co-CEO, for Endo Pharmaceuticals. In his earlier career, Charles held finance and operational positions at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom